Diagnostic techniques and prognostic indicators

Investigations of the Serum Free Light Chain Ratio According to the Updated 2014 IMWG Diagnostic Criteria for Multiple Myelomain Korean Patients with Newly Diagnosed Multiple Myeloma. Yang HS et al. Clin Lab. 2017 Oct 1;63(10):1765-1769. doi: 10.7754/Clin.Lab.2017.170341. Monitoring multiple myeloma by idiotype-specific peptide binders of tumor-derived exosomes. Iaccino E et al. Mol Cancer. 2017 Oct 13;16(1):159. doi: 10.1186/s12943-017-0730-8. Chromothripsis in Treatment Resistance in Multiple…

Details

Current treatments

Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma. Satin U et al. J Clin Apher. 2017 Oct 5. doi: 10.1002/jca.21591. [Epub ahead of print]. NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma. Jeker B et al. Bone Marrow Transplant. 2017 Oct 23. doi: 10.1038/bmt.2017.234. [Epub ahead of print]. Phase II…

Details

Complications of myeloma and its treatments

A Herald of Plasma Cell Myeloma: A Report of Malignant Plasma Cells Identified in Parathyroid Adenoma and a Review of Non-parathyroid Malignancies in Parathyroid Glands. Cracolici V et al. Head Neck Pathol. 2017 Oct 13. doi: 10.1007/s12105-017-0861-7. [Epub ahead of print]. Multiple Myeloma Presenting with Autoimmune Autonomic Ganglionopathy. Nakae Y et al. Intern Med. 2017 Oct 11. doi: 10.2169/internalmedicine.9096-17. [Epub ahead of print].…

Details

Biology and genetics

High NRF2 expression controls endoplasmic reticulum stress induced apoptosis in multiple myeloma. Sun Y et al. Cancer Lett. 2017 Oct 12. pii: S0304-3835(17)30629-8. doi: 10.1016/j.canlet.2017.10.005. [Epub ahead of print]. Characterization and use of the novel human multiple myelomacell line MC-b11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin a heavy chain. Walters DK et al. Exp Hematol. 2017 Oct 10. pii: S0301-472X(17)30814-7.…

Details

SMC approves restricted use of daratumumab monotherapy for relapsed and refractory myeloma

The Scottish Medicines Consortium (SMC) has approved the use of daratumumab (Darzalex®) monotherapy as a fourth line treatment option for relapsed and refractory myeloma patients in Scotland, who have previously received treatment with a proteasome inhibitor and immunomodulatory drug. This decision is based on the pooled analysis of results from two clinical trials, MMY2002 and…

Details

Supportive treatments

Acupuncture for reduction of symptom burden in multiple myelomapatients undergoing autologous hematopoietic stem cell transplantation: a randomized sham-controlled trial. Deng G et al. Support Care Cancer. 2017 Sep 17. doi: 10.1007/s00520-017-3881-7. [Epub ahead of print]. The treatment of paraprotein-related kidney disease. Hutchison CA et al. Curr Opin Nephrol Hypertens. 2017 Sep 6. doi: 10.1097/MNH.0000000000000369. [Epub ahead of print]. Surgical Roles for Spinal…

Details

General

Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Neelapu SS et al. Nat Rev Clin Oncol. 2017 Sep 19. doi: 10.1038/nrclinonc.2017.148. [Epub ahead of print]. Chimeric Antigen Receptor T-cell Therapies for Multiple Myeloma. Mikkilineni L et al. Blood. 2017 Sep 19. pii: blood-2017-06-793869. doi: 10.1182/blood-2017-06-793869. [Epub ahead of print]. Checking in: T cells against multiple myeloma. Kumar SK. Blood. 2017 Sep 7;130(10):1175-1176.…

Details